This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Find out more here.

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

Last updated on 12 May 2020

Research type

Clinical trial of an investigational medicinal product


Title

Randomised Evaluation of COVID-19 Therapy (RECOVERY)


Contact name

Professor Peter Horby


Sponsor

University of Oxford


Funder

UK Research & Innovation


New study or amendment to existing study

New


Research summary 

There are a number of possible treatments for COVID-19 infection available. The Randomised Evaluation of COVID Therapy (RECOVERY) trial will test whether these treatments work better than the treatments that are given in hospital at the moment. As well as normal hospital treatment patients with COVID-19 infection will either receive no additional experimental treatment, or will receive one of the following treatments:

  •  a combination of Lopinavir-Ritonavir (antiviral drugs)
  • interferon β1b (used to treat some kinds of multiple sclerosis)
  • low-dose corticosteroids (used to reduce inflammation)
  • hydroxychloroquine (similar to a drug used to treat malaria).

The trial is designed so that it can also test other possible treatments as they become available.

Information on time in hospital, the number of deaths in hospital, and the need for artificial ventilation will be collected.  The study hopes to identify effective treatments within three months. Information is available at https://www.recoverytrial.net/


IRAS ID

281712


Registry entries

EudraCT 2020-001113-21

ISRCTN number ISRCTN16912075


REC name

Cambridge East


REC reference

20/EE/0101


Date approved

17/03/2020 (new application) and 24/03/2020 (amendment)


Back to approved covid-19 research

Back to approved covid-19 research